Quick Answer
Neumora Therapeutics, Inc. reported Stockholders Equity of $103.87 million for fiscal year 2025.
Neumora Therapeutics, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $103.87M | -63.8% |
| 2024 | $287.06M | -38.8% |
| 2023 | $469.08M | +205.0% |
| 2022 | -$446.85M | -37.4% |
| 2021 | -$325.22M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $132.16M | -58.8% | -27.7% |
| June 30, 2025 | $182.88M | -52.0% | -19.9% |
| March 31, 2025 | $228.36M | -46.2% | -20.4% |
| December 31, 2024 | $287.06M | -38.8% | -10.5% |
| September 30, 2024 | $320.74M | -37.4% | -15.9% |
| June 30, 2024 | $381.26M | +174.2% | -10.2% |
| March 31, 2024 | $424.54M | +188.8% | -9.5% |
| December 31, 2023 | $469.08M | +205.0% | -8.5% |
- Neumora Therapeutics, Inc. showed a decrease of -63.8% in Stockholders Equity compared to the prior fiscal year.
- Over the 2021–2025 period, Neumora Therapeutics, Inc.’s stockholders equity has grown by 131.9% (from -$325.22 million to $103.87 million).
- The most recent figure is from Neumora Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: